Comparative Pharmacology
Head-to-head clinical analysis: CLOXAPEN versus LAROTID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOXAPEN versus LAROTID.
CLOXAPEN vs LAROTID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cloxapen inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBPs involved in the transpeptidation step of peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
Oral: 250-500 mg every 6 hours. IV: 1-2 g every 4-6 hours.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
None Documented
None Documented
Terminal elimination half-life 1.5-2 hours; prolonged to 2.5-4 hours in severe renal impairment; clinical context: requires frequent dosing in normal renal function
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
Renal 70-80% as unchanged drug and active metabolite; biliary 5-10%; fecal <5%
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic